Table 33 (abstract P86). Clinical and treatment characteristics
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
N = 88 | |
|---|---|
JIA subtype, n (%) | |
Systemic 10 (11,4) | |
Persistent oligoarticular 43 (48.9) | |
Extended oligoarticular 14 (15.9) | |
Polyarticular 21 (23.8) | |
Disease duration (years), mean ± SD | 6,3 ± 3,6 |
Inflammatory activity duration (weeks), median (IR) | 53 (32–109) |
Synthetic DMARDs treatment, n (%) | 85 (96.5) |
Biological DMARDs treatment, n (%) | 40 (45.5) |
Systemic corticosteroids, n (%) | 79 (89.7) |
Duration corticosteroids (days), median (IR) | 122 (55–178) |
Median corticosteroids dose (mg/kg/day), median (IR) | 0.34 (0.21–1.15) |